Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when BIAF files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsbioAffinity Technologies receives Mexican patent allowance for lung cancer detection method
Filed May 27, 2026 · Period ending May 27, 2026 · ~1 min read
Key Changes
-
medium
The Mexican Institute of Industrial Property has allowed a patent application covering methods to predict lung cancer likelihood using flow cytometry technology, strengthening the company's international IP portfolio.
Item 7.01 Press Release view on EDGAR → -
medium
This patent allowance expands bioAffinity's intellectual property protection beyond the U.S., potentially creating barriers to competition in the Mexican market for its diagnostic technology.
Item 7.01 view on EDGAR →
Summary
bioAffinity Technologies announced it has received notification that a patent application has been allowed in Mexico covering its methods for predicting lung cancer using flow cytometry. This represents an expansion of the company's intellectual property protection into international markets, specifically Mexico. For retail investors, patent allowances are meaningful because they can create competitive moats and potentially enable licensing revenue or partnerships in new geographic markets.
The technology at issue—flow cytometry-based lung cancer prediction—appears to be core to bioAffinity's diagnostic platform. Investors should watch for the formal patent grant (allowance is not yet issuance), any commercial partnerships or regulatory approvals in Mexico, and whether the company pursues similar patent protection in other Latin American markets.
Section-by-Section Diff
Event · Item 8.01 — Other Events
Item 8.01 — Other Events filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
bioAffinity Technologies, Inc., a Delaware corporation, issued a press release announcing that it has received notification of allowance from the Mexican Institute of Industrial Property for a patent application related to methods of predicting the likelihood of lung cancer using flow cytometry.
The company received notification that a patent application has been allowed in Mexico. This patent covers methods for predicting lung cancer likelihood using flow cytometry technology. Patent allowances can strengthen intellectual property protection and competitive positioning in international markets.
Event · Item 9.01 — Financial Statements and Exhibits
bioAffinity Technologies filed an 8-K attaching a press release dated May 27, 2026; no material event details disclosed in filing body.
Added in current filing · verify on EDGAR →
Press Release issued by bioAffinity Technologies, Inc., dated May 27, 2026
The 8-K references an attached press release dated May 27, 2026, but the filing body does not disclose the content or subject matter of that release. Without the exhibit text, the nature and materiality of the disclosed event cannot be determined from this filing.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · May 28, 2026 · How we verify